A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer

Cancer Letters

Volumn 310, Issue 2, 2011, Pages 134-139

  Zhao, Lin ^a   Bai, Chunmei ^a   Shao, Yajuan ^a   Guan, Mei ^a   Jia, Ning ^a   Xiao, Yi ^a   Qiu, Huizhong ^a   Zhang, Fuquan ^a   Yang, Ti ^a   Zhong, Guangxi ^a   Chen, Shuchang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Neoadjuvant chemoradiotherapy; Rectal cancer; XELOX regimen

Indexed keywords

ALANINE AMINOTRANSFERASE; CAPECITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANAL PAIN; ANEMIA; ANUS DISEASE; ANUS PAIN; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION INDUCED EMESIS; RASH; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; SIDE EFFECT; THROMBOCYTOPENIA; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT IRRITATION; URINARY URGENCY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS;

EID: 80051684442     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.026     Document Type: Article

References (37)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Minsky B.D., Mies C., Recht A., Rich T.A., Chaffey J.T. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 1988, 61:1408-1416.
3. Havenga K., Maas C.P., DeRuiter M.C., Welvaart K., Trimbos J.B. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Semin. Surg. Oncol. 2000, 18:235-243.
4. Gerard J.P., Conroy T., Bonnetain F., Bouche O., Chapet O., Closon-Dejardin M.T., Untereiner M., Leduc B., Francois E., Maurel J. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 2006, 24:4620-4625.
5. Bosset J.F., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., Bardet E., Beny A., Briffaux A., Collette L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J. Clin. Oncol. 2005, 23:5620-5627.
6. Ruo L., Tickoo S., Klimstra D.S., Minsky B.D., Saltz L., Mazumdar M., Paty P.B., Wong W.D., Larson Sm., Cohen A.M., Guillem J.G. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann. Surg. 2002, 236:75-81.
7. Vecchio F.M., Valentini V., Minsky B.D., Padula G.D., Venkatraman E.S., Balducci M., Micciche F., Ricci R., Morganti A.G., Gambacorta M.A., Maurizi F., Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62(3):752-760.
8. Chan A.K., Wong A., Jenken D., Heine J., Buie D., Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61(3):665-677.
9. Kuo L.J., Liu M.C., Jian J.J., Horng C.F., Cheng T.I., Chen C.M., Fang W.T., Chumg Y.L. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?. Ann. Surg. Oncol. 2007, 14(10):2766-2772.
10. Capirci C., Valentini V., Cionini L., De Paoli A., Rodel C., Glynne-Jones R., Coco C., Romano M., Mantello G., Palazzi S., Mattia Fo., Friso M.L., Genovesi D., Vidali C., Gambacorta M.A., Buffoli A., Lupattelli M., Favretto M.S., La Torre G. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72(1):99-107.
11. Kelly H., Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J. Clin. Oncol. 2005, 23:4553-4560.
12. Koeberle D., Burkhard R., von Moos R., Winterhalder R., Hess V., Heitzmann F., Ruhstalller T., Terraciano L., Neuweiler J., Bieri G., Rust C., Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 2008, 98:1204-1209.
13. Hospers G.A., Punt C.J., Tesselaar M.E., Cats A., Havenga K., Leer J.W., Marijnen C.A., Jansen E.P., Van Krieken H.H., Wiggers T., Van de Velde C.J., Mulder N.H. Preoperative chemoradiotherapy with capecitabine and oxalipatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann. Surg. Oncol. 2007, 14:2773-2779.
14. Chau I., Brown G., Cunningham D., Tait D., Wotherspoon A., Norman A.R., Tebbutt N., Hill M., Ross P.J., Massey A., Oates J. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol. 2006, 24:668-674.
15. Machiels J.P., Duck L., Honhon B., Coster B., Coche J.C., Scalliet P., Humblet Y., Aydin S., Kerger J., Remouchamps V. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann. Oncol. 2005, 16:1898-1905.
16. Fakih M.G., Bullarddunn K., Yang G.Y., Pendyala L., Toth K., Andrews C., Rustum Y.M., Ross M.E., Levea C., Puthillath A., Park Y.M., Rajput A. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72(3):650-657.
17. Carlomagno C., Farella A., Bucci L., D'Armiento F.P., Pesce G., Pepe S., Cannella L., Pacelli R., De Stefano A., Solla R., D'Armiento M.R., De Placido S. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann. Oncol. 2009, 20(5):906-912.
18. Ofner D., Devries A.F., Schaberl-Moser R., Greil R., Rabl H., Tschmelitsch J., Zitt M., Kapp K.S., Fastner G., Keil F., Eisterer W., Jäger R., Offner F., Gnant M., Thaler J. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT3NxM0, low rectal cancer: a phase II study. Strahlenther. Onkol. 2011, 187(2):100-107. TAKO 05/ABCSG R-02 Trial Investigators.
19. Gérard J.P., Azria D., Gourgou-Bourgade S., Martel-Laffay I., Hennequin C., Etienne P.L., Vendrely V., François E., de La Roche G., Bouché O., Mirabel X., Denis B., Mineur L., Berdah J.F., Mahé M.A., Bécouarn Y., Dupuis O., Lledo G., Montoto-Grillot C., Conroy T.J. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase II trial ACCORD 12/0405-Prodige. J. Clin. Oncol. 2010, 28(10):1638-1644.
20. Fernández-Martos C., Pericay C., Aparicio J., Salud A., Safont M., Massuti B., Vera R., Escudero P., Maurel J., Marcuello E., Mengual J.L., Saigi E., Estevan R., Mira M., Polo S., Hernandez A., Gallen M., Arias F., Serra J., Alonso V. Phase II, randomized study of concomitant chemoraditherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal caner: grupo cancer de recto 3 study. J. Clin. Oncol. 2010, 28(5):859-865.
21. Dworak O., Keilholz L., Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 1997, 12:19-23.
22. Husband J.E., Schwartz L.H., Spencer J., Ollivier L., King D.M., Johnson R., Reznek R. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br. J. Cancer 2004, 90:2256-2260.
23. NCI Common Toxicity Criteria for Adverse Events (CTCAE) v3.0. (accessed 10.04.08). http://www.fda.gov/CDER/cancer/toxicityframe.htm.
24. Colorectal Cancer Collaborative Group Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001, 358:1291-1304.
25. Camma C., Giunta M., Fiorica F., Pagliaro L., Craxi A., Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 2000, 284:1008-1015.
26. C. Aschele, C. Pinto, S. Cordio, et al., Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Reto (STAR)-01 randomized phase III trial, ASCO Abstract #4008, 2009.
27. Park Y.J., Oh B.R., Lim S.W., Huh J.W., Joo J.K., Kim Y.J., Kim H.R. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J. Korean Soc. Coloproctol 2010, 26(4):279-286.
28. Topova L., Hellmich G., Puffer E., Schubert C., Christen N., Boldt T., Wiedemann B., Witzigmann H., Stelzner S. Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis. Colon Rectum 2011, 54(4):401-411.
29. Chari R.S., Tyler D.S., Anscher M.S., Russell L., Clary B.M., Hathorn J., Seigler H.F. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann. Surg. 1995, 221:778-786.
30. Minsky B.D., Cohen A.M., Kemeny N., Enker W.E., Kelsen D.P., Reichman B., Saltz L., Sigurdson E.R., Frankel J. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J. Clin. Oncol. 1992, 10:79-84.
31. Ngan S.Y., Burmeister B.H., Fisher R., Rischin D., Schache D.J., Kneebone A., MacKay J.R., Joseph D., Bell A., Goldstein D. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a phase II trial for the Trans-Tasman Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50:883-887.
32. Janjan N.A., Crane C., Feig B.W., Cleary K., Dubrow R., Curley S., Vauthey J.N., Lynch P., Ellis L.M., Wolff R., Lenzi R. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am. J. Clin. Oncol. 2001, 24:107-112.
33. Bosset J.F., Magnin V., Maingon P., Mantion G., Pelissier E.P., Mercier M., Chaillard G., Horiot J.C. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46:323-327.
34. Gerard J.P., Chapet O., Nemoz C., Romestaing P., Mornex F., Coquard R., Barbet N., Atlan D., Adeleine P., Freyer G. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J. Clin. Oncol. 2003, 21:1119-1124.
35. Valentini V., Coco C., Cellini N., Picciocchi A., Genovesi D., Mantini G., Barbaro B., Cogliandolo S., Mattana C., Ambesi-Impiombato F., Tedesco M., Cosimelli M. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40(5):1067-1075.
36. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., Martus P., Tschmelitsch J., Hager E., Hess C.F., Karstens J.H., Liersch T., Schmidberger H., Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004, 351:1731-1740.
37. Enker W.E., Merchant N., Cohen A.M., Lanouette N.M., Swallow C., Guillem J., Paty P., Minsky B., Weyrauch K., Quan S.H. Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann. Surg. 1999, 230:544-552.